We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ebolavirus Found in Semen Months After Symptom Onset

By LabMedica International staff writers
Posted on 04 Nov 2015
Print article
Image: Colorized transmission electron micrograph (TEM) revealed some of the ultrastructural morphology displayed by an Ebolavirus virion with supplemented spermatozoa (Photo courtesy of Frederick A. Murphy/CDC, and Graphic by Mark Murrman).
Image: Colorized transmission electron micrograph (TEM) revealed some of the ultrastructural morphology displayed by an Ebolavirus virion with supplemented spermatozoa (Photo courtesy of Frederick A. Murphy/CDC, and Graphic by Mark Murrman).
The main mode of transmission is direct contact with the blood or body fluids of a person with Ebolavirus disease (EVD) or from the body of a person who died from EVD; however, Ebolavirus can persist in the body fluids of survivors during convalescence, which may result in transmission of the virus.

Previously, survivors of EVD were told to practice sexual abstinence or to use a condom for three months after recovery. These recommendations were based on virus-isolation results from semen specimens obtained from eight survivors of EVD or Marburgvirus disease in previous epidemics in which the longest period that infectious virus was found in semen after the onset of symptoms was 82 days.

A large international team of scientist led by those from the Sierra Leone Ministry of Health (Freetown, Sierra Leone) recruited a convenience sample of 100 male survivors from the Western Area District of Sierra Leone, which includes the capital of Freetown. They identified study participants who, at informational events that were held in conjunction with survivor associations, indicated interest in participation, as well as persons who were referred from Ebola treatment centers. A member of the study team administered a questionnaire to all the participants at the time of enrollment to gather information about their EVD episode, self-reported health status, sexual behavior, and sociodemographic characteristics, and the date of EVD onset was self-reported.

Semen specimens were collected and refrigerated at 5 °C to 8 °C for no longer than three days and transported to the field laboratory. The team performed quantitative reverse transcription polymerase chain reaction (RT-PCR) testing using Ebolavirus–specific gene targets (NP and VP40) and the human β2-microglobulin (B2M) gene. A specimen was considered positive if the VP40 and NP gene targets were both detected within 40 cycles of replication. The specimen was considered to be negative if neither Ebolavirus gene targets were detected nor the findings with respect to B2M status were positive. The findings were ruled to be indeterminate if either the VP40 or the NP gene target was detected but not both. Amplification of B2M served as an extraction control and RNA quality control.

A total of 46 of the 93 men (49%) had a specimen that was positive on quantitative RT-PCR. Ebolavirus RNA was detected in the semen of all 9 men from whom a specimen was obtained during the first three months after the onset of illness, in the semen of 26 of 40 men (65%) from whom a specimen was obtained at four to six months, and in the semen of 11 of 43 men (26%) from whom a specimen was obtained at seven to nine months. The longest time after the onset of a participant’s EVD symptoms that a semen specimen obtained at baseline remained positive on quantitative RT-PCR was 284 days. Indeterminate results were encountered in 10 initial specimens in the range of 152 to 273 days after the onset of symptoms.

Bruce Aylward, MD, an Assistant Director-General at the World Health Organization (Geneva, Switzerland) said, “These results come at a critically important time reminding us that while Ebola case numbers continue to plummet, Ebola survivors and their families continue to struggle with the effects of the disease. This study provides further evidence that survivors need continued, substantial support for the next 6 to12 months to meet these challenges and to ensure their partners are not exposed to potential virus.” The study was published on October 14, 2015, in the New England Journal of Medicine (NEJM).

Related Links:

Sierra Leone Ministry of Health 
World Health Organization 


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Crypto + Giardia One Step Combo Card Test
CerTest Crypto + Giardia
New
Refrigerated Microtube Homogenizer
BeadBlaster 24R

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.